New Risk • Apr 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Shareholders have been substantially diluted in the past year (190% increase in shares outstanding). Market cap is less than US$10m (US$5.35m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$147k net loss in 2 years). Share price has been volatile over the past 3 months (15% average weekly change). New Risk • Apr 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 190% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (190% increase in shares outstanding). Market cap is less than US$10m (US$5.35m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$147k net loss in 2 years). Share price has been volatile over the past 3 months (15% average weekly change). Duyuru • Apr 24
Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8 million. Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,962,963
Price\Range: $1.35
Security Name: Common Warrants
Security Type: Equity Warrant
Securities Offered: 2,962,963
Price\Range: $1.35 New Risk • Apr 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Market cap is less than US$10m (US$3.55m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$147k net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). New Risk • Feb 12
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Market cap is less than US$10m (US$4.93m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$147k net loss in 2 years). Reported Earnings • Feb 12
Third quarter 2026 earnings: EPS and revenues miss analyst expectations Third quarter 2026 results: US$0.48 loss per share (improved from US$0.63 loss in 3Q 2025). Revenue: US$4.35m (up 22% from 3Q 2025). Net loss: US$819.0k (loss narrowed 12% from 3Q 2025). Revenue missed analyst estimates by 21%. Earnings per share (EPS) also missed analyst estimates by 66%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings. Duyuru • Jan 29
Sonoma Pharmaceuticals, Inc. Announces Board and Committee Changes, Effective January 28, 2026 Sonoma Pharmaceuticals, Inc. announced that effective January 28, 2026, Dr. Jay Birnbaum retired from the Board of Directors. Dr. Birnbaum will continue to serve the Company pursuant to a consulting agreement, for a term of one year. Effective January 28, 2026, the Board appointed Ms. Vanessa Jacoby as a director of Company. She will replace Dr. Birnbaum as an independent director. Ms. Jacoby was also appointed as Chairperson of Audit Committee and as a non-chairperson member of Compensation Committee. Ms. Jacoby currently serves as the Chief Business and Financial Officer for Quanta Therapeutics, Inc., a clinical stage biotechnology company focused on developing best-in-class small molecules inhibitors for RAS-driven cancers. Prior to joining Quanta, Ms. Jacoby served as Chief Financial Officer of Shoreline Biosciences. Prior to joining Shoreline, Ms. Jacoby served as Chief Accounting Officer of Avidity Biosciences, Inc. Prior to Avidity, Ms. Jacoby was Vice President, Finance at PharmAkea, which was acquired by Galecto in 2019. Prior to that, she served as Director of Accounting and Controller at BCI, Inc., and held senior financial roles at Artes Medical and Verenium Corporation. Before joining industry, Ms. Jacoby was an auditor for Ernst & Young. Ms. Jacoby received her M.B.A. from National University and B.S. degree in Business Administration from Fundação Armando Alvares Penteado, Sao Paulo, Brazil. She is a Certified Public Accountant with the State of California (inactive). She currently serves on the board of trustees for the Ruben H. Fleet Science Center in San Diego and is on the board for the Association of Bioscience Financial Officers (ABFO) Southwest chapter. Breakeven Date Change • Dec 31
Forecast breakeven date pushed back to 2028 The 2 analysts covering Sonoma Pharmaceuticals previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 47% per year to 2027. The company is expected to make a profit of US$121.4k in 2028. Average annual earnings growth of 83% is required to achieve expected profit on schedule. Reported Earnings • Nov 05
Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2026 results: US$0.32 loss per share (improved from US$0.59 loss in 2Q 2025). Revenue: US$5.60m (up 57% from 2Q 2025). Net loss: US$534.0k (loss narrowed 13% from 2Q 2025). Revenue exceeded analyst estimates by 32%. Earnings per share (EPS) missed analyst estimates by 3.2%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 08
First quarter 2026 earnings: EPS misses analyst expectations First quarter 2026 results: US$0.76 loss per share. Revenue: US$4.02m (up 18% from 1Q 2025). Net loss: US$1.24m (loss widened 8.6% from 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 49%. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Pharmaceuticals industry in the US. Duyuru • Jul 14
Sonoma Pharmaceuticals, Inc., Annual General Meeting, Aug 27, 2025 Sonoma Pharmaceuticals, Inc., Annual General Meeting, Aug 27, 2025. Location: 5445 conestoga court, unit 150,co, 80301, boulder United States Duyuru • Jun 19
Sonoma Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt Sonoma Pharmaceuticals, Inc. filed its Annual on Jun 17, 2025 for the period ending Mar 31, 2025. In this report its auditor, Frazier & Deeter, LLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Reported Earnings • Jun 18
Full year 2025 earnings released: US$2.79 loss per share (vs US$10.64 loss in FY 2024) Full year 2025 results: US$2.79 loss per share (improved from US$10.64 loss in FY 2024). Revenue: US$14.3m (up 12% from FY 2024). Net loss: US$3.46m (loss narrowed 28% from FY 2024). New Risk • May 14
New major risk - Revenue and earnings growth Earnings have declined by 2.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 2.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (107% increase in shares outstanding). Market cap is less than US$10m (US$4.96m market cap). New Risk • Mar 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (107% increase in shares outstanding). Market cap is less than US$10m (US$3.22m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$3.2m net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Reported Earnings • Feb 06
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: US$0.63 loss per share. Revenue: US$3.56m (up 14% from 3Q 2024). Net loss: US$928.0k (loss widened 7.2% from 3Q 2024). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 8.7%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in the US. Duyuru • Nov 22
Sonoma Pharmaceuticals, Inc. Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States Sonoma Pharmaceuticals, Inc. announced the relaunch of its prescription dermatology and eye care products lines. The prescription-strength products include: Acuicyn® Eyelid & Eyelash Hygiene, Epicyn® Facial Cleanser, Levicyn® Dermal Spray, Levicyn® Gel, Levicyn® Spray Gel and Celacyn® Scar Management Gel. In addition, Lasercyn® Dermal Spray and Lasercyn® Gel are available for over-the-counter use. These hypochlorous acid-based products were previously sold through a distributor to physicians, clinics and pharmacies. The products will now be available directly from Sonoma. All products will be available December 9, 2024 and can be pre-ordered prior to that date. Duyuru • Nov 12
Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel Sonoma Pharmaceuticals, Inc. announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based hydrogel, including improved biocompatibility and extended shelf life. Per this new clearance, Sonoma's Microdacyn Hydrogel can be used under the supervision of a healthcare professional for management of wounds associated with dermal irritation, sores, injuries and ulcers of dermal tissue, for use on first and second degree burns, and diabetic ulcers, and for the management of mechanically or surgically debrided wounds. It is also indicated for OTC use on minor skin irritations, lacerations, abrasions and minor burns, including for the management of irritation from sunburn. The new 510(k) clearance process also included more rigorous biocompatibility testing, and the clearance applies to 50mL bottles with a shelf life of 24 months. Reported Earnings • Nov 08
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2025 results: US$0.59 loss per share (improved from US$5.75 loss in 2Q 2024). Revenue: US$3.58m (up 31% from 2Q 2024). Net loss: US$610.0k (loss narrowed 59% from 2Q 2024). Revenue missed analyst estimates by 8.3%. Earnings per share (EPS) exceeded analyst estimates by 34%. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. Duyuru • Nov 01
Sonoma Pharmaceuticals, Inc. to Exhibit At MEDICA 2024 in Dusseldorf Sonoma Pharmaceuticals, Inc. announced that it will be exhibiting at MEDICA 2024 in Dusseldorf, Germany November 11-14, 2024. MEDICA is considered the largest and most prestigious medical trade fair in the world, expected to attract over 120,000 visitors from more than 70 countries and over 5,300 exhibitors, showcasing the latest innovations in medical technology, diagnostics, and healthcare IT. The event brings together professionals, fostering valuable networking opportunities with industry peers, potential partners, and customers from around the globe. It serves as a comprehensive platform for growth, learning, and collaboration within the healthcare sector. Sonoma Pharmaceuticals is aiming to expand its distributor network and is eager to showcase its products and technologies to a global audience, forging valuable connections with potential partners and industry customers. Interested parties are invited to visit Sonoma Pharmaceuticals' booth (F12-5) in Hall 15 to learn about its patented, innovative, safe, and effective products for the treatment of scar management, atopic dermatitis, and acne, as well as wound care and eyelid infection. Duyuru • Sep 20
Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Sonoma Pharmaceuticals, Inc. announced that it received a formal determination letter from Nasdaq notifying Sonoma that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market and the matter is now closed. As previously reported, On September 22, 2023, Sonoma received a letter from Nasdaq indicating that it did not comply with the $1.00 minimum closing bid price requirement for its common stock for continued listing on the Nasdaq Capital Market. On March 21, 2024, Nasdaq granted the company an additional 180 calendar days, or until September 16, 2024, to regain compliance with the listing rule. Effective with the opening of the market on August 30, 2024, the company implemented a 1-for-20 reverse stock split. The closing bid price of Sonoma's common stock exceeded the required $1.00 per share minimum over the subsequent 10 business days. Accordingly, Sonoma has regained compliance and is no longer subject to delisting at this time. Duyuru • Sep 18
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution Sonoma Pharmaceuticals, Inc. announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based solution, including specific over-the-counter indications for the face, eyelid and eyelashes. Per this new clearance, Sonoma's Microcyn wound care solution can be used for OTC management of minor skin abrasions, lacerations and irritations, and intact skin on the face, eyelid and eyeashes. Sonoma believes these are the strongest OTC eye care claims in the HOCl industry. Additionally, the new claim referencing the face will expand how Sonoma can market its OTC dermatology products. To support this 510(k) clearance, Sonoma was able to demonstrate safety, efficacy and stability for the 2 ounce product size, offering Sonoma a new opportunity to package certain of its products in smaller sizes appealing to consumers. Duyuru • Aug 27
Sonoma Pharmaceuticals, Inc. and Its Partner, the MicroSafe Group DMCC, Announce That the Australian Therapeutic Goods Administration Approves Extended Claims for Nanocyn Disinfectant and Sanitizer Sonoma Pharmaceuticals, Inc. and its partner, the MicroSafe Group DMCC, announced that the Australian Therapeutic Goods Administration has approved extended claims for Nanocyn Disinfectant and Sanitizer, which is manufactured by Sonoma for its partner MicroSafe using Sonoma's patented Microcyn technology. Nanocyn was previously approved by the TGA and entered into The Australian Register of Therapeutic Goods with a 15 second kill time against SARS-CoV-2 (COVID 19), and a 30 second kill time against Norovirus (Gastro), Influenza A (H1N1), and bacteria, such as Staphylococcus aureus. E. coli, Pseudomonas aeruginosa. The TGA has now also approved Nanocyn for use against Candida auris (C. auris) and Clostritium Difficile (C. diff.) in ten minutes. The U.S. Environmental Protection Agency has previously approved Nanocyn® as an effective bactericidal (MRSA, Salmonella), virucidal (Mpox, SARS-CoV-2), and fungicidal disinfectant for use on pre-cleaned, hard, non-porous surfaces. Reported Earnings • Aug 11
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: US$0.067 loss per share (improved from US$0.29 loss in 1Q 2024). Revenue: US$3.39m (down 1.1% from 1Q 2024). Net loss: US$1.14m (loss narrowed 19% from 1Q 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 40%. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in the US. Duyuru • Jun 24
Sonoma Pharmaceuticals, Inc., Annual General Meeting, Aug 14, 2024 Sonoma Pharmaceuticals, Inc., Annual General Meeting, Aug 14, 2024. Location: 5445 conestoga court, unit 150, colorado 80301., boulder, United States Reported Earnings • Jun 18
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: US$0.53 loss per share (improved from US$1.52 loss in FY 2023). Revenue: US$12.7m (down 4.0% from FY 2023). Net loss: US$4.84m (loss narrowed 6.1% from FY 2023). Revenue missed analyst estimates by 13%. Earnings per share (EPS) exceeded analyst estimates by 40%. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. Duyuru • May 10
Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores Sonoma Pharmaceuticals, Inc. announced the launch of its MicrocynAH animal health care products in the Menards chain of home improvement stores in the United States. Menards is a family-owned company started in 1958 and headquartered in Eau Claire, Wisconsin. It has more than 300 home improvement stores located in Illinois, Indiana, Iowa, Kansas, Kentucky, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, West Virginia, Wisconsin, and Wyoming. Sonoma's MicrocynAH products are distributed in the U.S. and Canada through its partner, Compana Pet Brands. MicrocynAH products available through Menards stores and online include: Wound & Skin Care Spray, Wound & Skin Care Hydrogel, Eye & Ear Wash, Anti-Itch Gel Spray with Dimethicone and Hot Spot Gel Spray with Dimethicone. Duyuru • Mar 25
Nasdaq Grants Extension to Sonoma Pharmaceuticals to Regain Minimum Bid Price Requirement On March 21, 2024, Sonoma Pharmaceuticals, Inc. (the Company") received a notice (the Extension Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until September 16, 2024 to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the Rule"). The Extension Notice has no immediate effect on the listing of the Company's common stock. As previously disclosed in the Current Report on Form 8-K filed on September 28, 2023 with the Securities and Exchange Commission, the Company received a notice from Nasdaq on September 22, 2023 informing the Company that because the closing bid price for the Company's common stock listed on Nasdaq was below $1.00 per share for 30 consecutive business days, the Company did not comply with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under the Rule. That notification had no immediate effect on the listing of the Company's common stock. The Company initially had a period of 180 calendar days, or until March 20, 2024, to regain compliance with the Rule. The Company did not regain compliance with the Rule by such date and proactively notified Nasdaq of its intent to cure the deficiency and requested an additional 180 calendar day period to regain compliance with the Rule. If at any time before September 16, 2024 the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has achieved compliance with the Rule, unless Nasdaq exercises its discretion to extend this 10-day period pursuant to Nasdaq Listing Rule 5810(c)(3). If compliance with the Rule cannot be demonstrated to Nasdaq's satisfaction by September 16, 2024, Nasdaq will provide written notification that the Company's common stock will be delisted. At that time, the Company may appeal Nasdaq's delisting determination to a Nasdaq Hearings Panel. The Company intends to continue actively monitoring the bid price for its common stock between now and September 16, 2024 and will consider available options to resolve the deficiency and regain compliance with the Rule. These options include effecting a reverse stock split, if necessary. There is no assurance, however, that the Company will regain compliance with the Rule or that the Company's common stock will not be delisted from Nasdaq. Duyuru • Mar 09
Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.785679 million. Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.785679 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Reported Earnings • Feb 10
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2024 results: US$0.079 loss per share (improved from US$0.62 loss in 3Q 2023). Revenue: US$3.14m (up 6.6% from 3Q 2023). Net loss: US$866.0k (loss narrowed 55% from 3Q 2023). Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 62%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in the US. Duyuru • Jan 23
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use Sonoma Pharmaceuticals, Inc. announced the launch of LumacynTM Clarifying Mist direct to consumers for over-the-counter use in the United States. Lumacyn Clarifying Mist is an anti-inflammatory and antibacterial spray that calms irritated skin using Sonoma's patented stabilized hypochlorous acid. As a daily use toner, Lumacyn is specially formulated to soothe the skin, reduce redness and irritation, and manage blemishes by reducing infection. Lumacyn is all-natural, pH balanced, free of fragrances and additives, and safe for all ages and skin types. Duyuru • Dec 16
Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.392077 million. Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.392077 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • Nov 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$4.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.5m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (341% increase in shares outstanding). Market cap is less than US$10m (US$2.13m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$2.5m net loss in 2 years). Reported Earnings • Nov 16
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: US$0.29 loss per share. Revenue: US$2.73m (down 18% from 2Q 2023). Net loss: US$1.48m (loss widened 46% from 2Q 2023). Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 21%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US. Duyuru • Nov 04
Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference Sonoma Pharmaceuticals, Inc. announced the U.S. launch of its intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures. Sonoma previously launched its pulse lavage irrigation treatment solution in Europe and is introducing this product to the United States at the Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas. Demonstrations will be available November 3-5 at booth 118. The product is expected to be ready for commercial use in the U.S. in November 2023. Sonoma developed this new application of its wound care technology in response to an unmet need for a non-toxic irrigation solution that can prevent infection and improve healing time. This product replaces commonly used non-antimicrobial saline and aggressive rinsing solutions with safe and effective Microcyn®? Technology. Microcyn®? Technology assists in the reduction of microorganisms, is non-toxic, and has regenerative properties, making it critical in preventing infection and promoting wound healing. Sonoma's pulse lavage container is also cost competitive with IV bags, the current standard of care. The new application complements a variety of pulse lavage irrigation treatments, including abdominal, laparoscopic, and periprosthetic joint infection procedures. The intraoperative pulse lavage irrigation treatments is safe for soft tissues, mucous membranes, bones, tendons, muscles, cartilage and even nerve tissue. The solution can be easily disposed without biohazard precautions and comes in a spikeable and unbreakable 5-liter container. Duyuru • Oct 28
Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million. Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 8,500,000
Price\Range: $0.2
Discount Per Security: $0.016 New Risk • Oct 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.1m free cash flow). Shareholders have been substantially diluted in the past year (67% increase in shares outstanding). Market cap is less than US$10m (US$2.67m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$3.0m net loss in 2 years). Share price has been volatile over the past 3 months (9.6% average weekly change). Duyuru • Sep 29
Sonoma Pharmaceuticals Receives Letter from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price for its Common Stock On September 22, 2023, Sonoma Pharmaceuticals, Inc. received a letter from the Listing Qualifications staff of The Nasdaq Stock Market LLC, notifying the company that, for the previous 30 consecutive business days, the company has failed to comply with Nasdaq Listing Rule 5550(a)(2), which requires the company to maintain a minimum bid price of $1 per share for the company's common stock. In accordance with Listing Rule 5810(c)(3)(A), Nasdaq has granted the company a period of 180 calendar days, or until March 20, 2024, to regain compliance with the Rule. The company may regain compliance with the Rule at any time during this compliance period if the minimum bid price for the company's common stock is at least $1 for a minimum of ten consecutive business days. The letter has no effect on the listing or trading of the company's common stock at this time. However, there can be no assurance that the company will be able to regain compliance with Listing Rule 5550(a)(2). In the event the company do not regain compliance with the Listing Rule prior to the expiration of the compliance period, the company may be eligible for additional time. To qualify, the company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of the company's intention to cure the deficiency during the second compliance period, by effecting a reverse split, if necessary. If the company meet these requirements, Nasdaq will inform the company that it has been granted an additional 180 calendar days. However, if it appears to the Staff of Nasdaq that the company will not be able to cure the deficiency, or if the company is otherwise not eligible, Nasdaq will provide notice that the company's securities will be subject to delisting. Breakeven Date Change • Sep 19
No longer forecast to breakeven The analyst covering Sonoma Pharmaceuticals no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$11.2m in 2024. New forecast suggests the company will make a loss of US$1.46m in 2026. New Risk • Aug 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.1m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (US$4.37m market cap). Duyuru • Aug 17
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced Sonoma Pharmaceuticals, Inc. announced that Reliefacyn Advanced Itch-Burn-Rash- Pain Relief Hydrogel has received the National Eczema Association (NEA) Seal of Acceptance. Reliefacyn Advanced is a direct-to-consumer product available for over-the-counter use. Reliefacyn effectively manages symptoms of eczema, or atopic dermatitis, including red bumps, itchy, painful and scaly rashes, shallow skin fissures and peeling. Reliefacyn's aloe vera like texture is also highly effective in soothing burns, including sunburns and burns from medical treatments, such as radiation. The gel adheres quickly to the skin, making it easy to apply without dripping or running, and leaves no residue. The Seal of Acceptance indicates that Reliefacyn Advanced meets the highest standards of the National Eczema Association, is free from known irritants and allergens and has undergone rigorous testing and scientific review. Products that receive the seal meet strict standards established by the NEA's Scientific Oversight Committee, a panel of leading dermatologists, allergists and eczema experts, and undergo testing for sensitivity, irritation and toxicity, as well as a review of ingredients and formulation data. Reported Earnings • Aug 13
First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.29 loss in 1Q 2023) First quarter 2024 results: US$0.29 loss per share (further deteriorated from US$0.29 loss in 1Q 2023). Revenue: US$3.43m (down 14% from 1Q 2023). Net loss: US$1.42m (loss widened 60% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Duyuru • Aug 04
Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board Sonoma Pharmaceuticals, Inc. (Formerly Known As Oculus Innovative Sciences, Inc.) announced the appointment of Dr. Hye Jin Chung MD, MMSc, Assistant Professor of Dermatology at Harvard Medical School in Boston and practicing dermatologist at Beth Israel Deaconess Medical Center, to the company's Scientific Advisory Board. Dr. Chung graduated with her MD from Yonsei University College of Medicine, Seoul, Korea in 2001, where she completed her residency and fellowship training in Dermatology. She finished her post-doctoral fellowship and residency in dermatology at Thomas Jefferson University Hospital, Philadelphia, PA, in 2014. Dr. Chung joined the faculty of Dermatology, at Boston University School of Medicine, upon completion of her dermatopathology fellowship at Boston Medical Center in 2016 and maintained dual roles within the Department of Dermatology, evaluating patients in the Faculty Practice of Boston Medical Center and the Skin Pathology Laboratory at Boston University School of Medicine. Currently, Dr. Chung is Assistant Professor of Dermatology at Harvard Medical School, Director of Skin of Color Clinic and Asian Skin Clinic, and Director of Cosmetic and Laser Surgery at Beth Israel Deaconess Medical Center. Dr. Chung has done extensive research in the field of scarring disorders, laser therapy, skin disorders in skin of color patients, and dermatopathology. She has clinical interests in acne, scar prevention and treatment, Asian skin diseases, cosmetic dermatology, laser therapy, and cutaneous surgery. For her accomplishments, Dr. Chung has received numerous awards including the Dermatology Foundation Research Grant, Skin of Color Research Grant, First Place in the 49th Korean Dermatology Board Examination, Intern of the Year, and Outstanding Role Model Award. Duyuru • Jul 15
Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller Effective July 17, 2023, Board of Directors of Sonoma Pharmaceuticals, Inc. appointed John Dal Poggetto as Controller. Mr. Dal Poggetto, age 52, served as Chief Financial Officer from 2019 to 2020 and as Executive Vice President of Finance from 2017 to 2019. Prior to that he was the Company’s Controller since 2002. He has extensive knowledge of Company’s business and operations. Reported Earnings • Jun 23
Full year 2023 earnings released: US$1.52 loss per share (vs US$1.92 loss in FY 2022) Full year 2023 results: US$1.52 loss per share. Revenue: US$13.3m (up 5.1% from FY 2022). Net loss: US$5.15m (loss widened 1.3% from FY 2022). Duyuru • Jun 09
Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union Sonoma Pharmaceuticals, Inc. announced a new application for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures. Sonoma developed this new application of its wound care technology in response to an unmet need for a non-toxic irrigation solution that can prevent infection and improve healing time. The intraoperative pulse lavage container is designed to be used in combination with a pulse lavage irrigation device, or flush gun, for abdominal, laparoscopic, orthopedic, and periprosthetic procedures. This product replaces commonly used non-antimicrobial saline and aggressive rinsing solutions with safe and effective Microcyn® Technology. Microcyn® Technology assists in the reduction of microorganisms, is non-toxic, and has regenerative properties, making it critical in preventing infection and promoting wound healing. Sonoma's pulse lavage container is also cost competitive with IV bags, the current standard of care. Sonoma developed the intraoperative pulse lavage irrigation treatment in close collaboration with the medical community and Sonoma's existing distribution partners in Europe and expects this new application will be met with wide acceptance. Sonoma is now accepting orders for the pulse lavage irrigation treatment solution, which is expected to be ready for commercial use in Europe in September 2023. Sonoma anticipates commercial launch in the U.S. in 2024. Reported Earnings • Feb 16
Third quarter 2023 earnings released: US$0.62 loss per share (vs US$0.31 loss in 3Q 2022) Third quarter 2023 results: US$0.62 loss per share (further deteriorated from US$0.31 loss in 3Q 2022). Revenue: US$2.94m (up 1.4% from 3Q 2022). Net loss: US$1.94m (loss widened 105% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Duyuru • Jan 05
Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas Sonoma Pharmaceuticals, Inc. announced that it has launched a line of office dispense products exclusively for skin care professionals. The products include Regenacyn® Plus, Reliefacyn® Plus, and Rejuvacyn® Plus, all in prescription strength formulations. Sonoma is targeting its officedistribution program to dermatology practices and medical spas. Clients will be able to purchase Sonoma's prescription strength products directly from their skin care professional, instead of making a separate trip to the pharmacy. Office dispense offers improved outcomes, convenience, and lower healthcare costs for clients while providing an additional source of income for skin care professionals. Sonoma's new products: Rejuvacyn® Plus Skin Repair Cooling Mist accelerates the skin's recovery following cosmetic or medical procedures such as Botox, fillers or other injections, non-ablative laser therapy procedures, hair removal, microdermabrasion therapy, superficial chemical peels, and facials. Rejuvacyn Plus protects vulnerable skin, accelerates healing, and soothes irritation and redness. Reliefacyn® Plus Itch-Burn-Rash-Pain Relief Hydrogel treats symptoms associated with eczema (atopic dermatitis), such as itching, burning, inflammation, redness and pain, as well as minor skin irritations, such as abrasions, rashes and burns. These products join Regenacyn® Plus Scar Management Hydrogel that was launched in September 2021. Regenacyn Plus is clinically proven to improve the look, feel and color of keloid and hypertrophic scars, while also relieving itch and pain and reducing the chance of infection. All of Sonoma's office dispense products are powered by Microcyn® technology, which is clinically-proven to accelerate healing, fight infection, and reduce itch, pain, redness and irritation that can result from cosmetic and medical procedures available from dermatologists and medical spas. Microcyn® products have no contra-indications and can be used with sunscreens and lotions as well as prescription products such as steroids, making them an easy and effective addition to any skin care regime. Reported Earnings • Nov 17
Second quarter 2023 earnings released: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022) Second quarter 2023 results: US$0.33 loss per share (further deteriorated from US$0.043 loss in 2Q 2022). Revenue: US$3.33m (down 11% from 2Q 2022). Net loss: US$1.02m (loss widened US$917.0k from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Independent Director Philippe Weigerstorfer was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 12
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2022 results: US$0.31 loss per share (down from US$0.30 loss in 3Q 2021). Revenue: US$2.90m (down 41% from 3Q 2021). Net loss: US$944.0k (loss widened 51% from 3Q 2021). Revenue exceeded analyst estimates by 5.7%. Earnings per share (EPS) missed analyst estimates by 23%. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 17
Second quarter 2022 earnings released: US$0.033 loss per share (vs US$0.075 profit in 2Q 2021) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: US$3.74m (down 35% from 2Q 2021). Net loss: US$100.0k (down 166% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Director Philippe Weigerstorfer was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Director Philippe Weigerstorfer was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Is New 90 Day High Low • Feb 17
New 90-day high: US$9.64 The company is up 41% from its price of US$6.82 on 18 November 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period. 
